Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03692429 |
| Title | alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK) |
| Acronym | alloSHRINK |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Celyad Oncology SA |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | BEL |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Moffit Cancer Center | NOT_YET_RECRUITING | Tampa | Florida | 33612 | United States | Details |
| Institut Jules Bordet | RECRUITING | Brussels | 1000 | Belgium | Details | |
| UZ Antwerpen | RECRUITING | Edegem | 2650 | Belgium | Details | |
| UZ Leuven | RECRUITING | Leuven | 3000 | Belgium | Details |